Stay updated with breaking news from Evaluating Rusfertide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with...
/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) today announced new data from its ongoing Phase 2 REVIVE study evaluating rusfertide in patients with...
/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies...
/PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today presented updated data from two ongoing Phase 2 studies...